Actively Recruiting
The Suitability of Tience4 for the Treatment of Acne Scars
Led by Linio Biotech Oy · Updated on 2026-01-28
20
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
Sponsors
L
Linio Biotech Oy
Lead Sponsor
C
Clinius Ltd
Collaborating Sponsor
AI-Summary
What this Trial Is About
The trial investigates the use of Tience4, a human-derived, cell-free adipose tissue product, for treating moderate to severe acne scars. This open-label, single-center study aims to assess the product's safety and effectiveness in improving acne scar appearance and skin quality, providing new options for individuals with long-lasting acne scars. The study is sponsored by Linio Biotech Oy and focuses on participants aged 18 to 40 years with acne scars at least three years old. Participants will receive three sessions of intradermal injections of Tience4 on one side of the face, administered on Day 0, Day 30, and Day 90. The untreated side of the face will be treated after the follow-up period. The treatment works by supplementing and replacing extracellular matrix deficiencies in the skin to support tissue repair. During the 12-month study, participants will undergo clinical assessments using a scarring grading system, patient self-evaluations, and VISIA4 skin analysis to track changes over time. Safety will be monitored through questionnaires assessing adverse reactions after each treatment and researcher evaluations. Follow-up visits will occur at multiple time points, including Day 180, to evaluate scar severity and overall skin condition.
CONDITIONS
Brief Title
The Suitability of Tience® for Treating Acne Scars
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy volunteers aged 18 to 40 years
- At least 3-year-old acne scars on the cheeks
You will not qualify if you...
- Pregnancy or nursing
- Cancer or ongoing cancer treatment
- Active skin disease
- Fitzpatrick skin type 4 to 6
- Use of strong medication for severe acne (e.g., Isotretinoin)
- Active acne or Herpes
- Use of antihistamine medication unless can be paused for 7 days during visits
- Use of biological medications
- Tendency for excessive scar formation
- Tendency for urticaria (hives)
- Use of systemic medication affecting immunity
- Autoimmune disease
- Known blood clotting disorders (e.g., von Willebrand disease)
- Allergy to the study product or its ingredients
- Smoking
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 3 months
Participants receive three intradermal injection sessions of the Tience® product on one side of the face to treat acne scars.
3 treatment visits on Day 0, Day 30, and Day 90
Duration - Up to 3 months after last treatment (Day 90 to Day 180)
Participants are monitored for safety and effectiveness of the treatment, including skin assessments and self-evaluations.
1 evaluation visit at Day 180 and safety assessments 7 days after each treatment
Trial Site Locations
Total: 1 location
1
Aava Kamppi Medical Centre
Helsinki, Finland, 001000
Actively Recruiting
Research Team
M
Minna Höst, Coordinator
L
Laura Bouchard, MD, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here